PR
MDGL icon

PSP Research’s Madrigal Pharmaceuticals MDGL Stock Holding History

PSP Research’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$322K Hold
600
– – 0.17% 44
2026
Q1 		$314K Sell
600
-292
-33% -$140K 0.22% 57
2025
Q4 		$519K Buy
+892
New +$456K 0.45% 66

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PSP Research's MDGL Position: Q2 2026 in Review

PSP Research held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 600 shares worth $322K. The position accounts for 0.17% of the portfolio, ranked #44.

PSP Research first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. The position peaked at $519K in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • PSP Research held 600 shares of Madrigal Pharmaceuticals worth $322K as of Q2 2026.
  • PSP Research left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up 0.17% of PSP Research's portfolio in Q2 2026, its #44 holding.
  • PSP Research first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Madrigal Pharmaceuticals position peaked at $519K in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.